Success Metrics

Clinical Success Rate
79.8%

Based on 257 completed trials

Completion Rate
80%(257/322)
Active Trials
201(27%)
Results Posted
39%(101 trials)
Terminated
65(9%)

Phase Distribution

Ph phase_2
315
43%
Ph phase_1
123
17%
Ph phase_3
128
17%
Ph phase_4
9
1%
Ph early_phase_1
4
1%
Ph not_applicable
84
11%

Phase Distribution

127

Early Stage

315

Mid Stage

137

Late Stage

Phase Distribution663 total trials
Early Phase 1First-in-human
4(0.6%)
Phase 1Safety & dosage
123(18.6%)
Phase 2Efficacy & side effects
315(47.5%)
Phase 3Large-scale testing
128(19.3%)
Phase 4Post-market surveillance
9(1.4%)
N/ANon-phased studies
84(12.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

76.5%

257 of 336 finished

Non-Completion Rate

23.5%

79 ended early

Currently Active

201

trials recruiting

Total Trials

734

all time

Status Distribution
Active(257)
Completed(257)
Terminated(79)
Other(141)

Detailed Status

Completed257
Recruiting143
unknown139
Terminated65
Active, not recruiting58
Not yet recruiting53

Development Timeline

Analytics

Development Status

Total Trials
734
Active
201
Success Rate
79.8%
Most Advanced
Phase 4

Trials by Phase

Early Phase 14 (0.6%)
Phase 1123 (18.6%)
Phase 2315 (47.5%)
Phase 3128 (19.3%)
Phase 49 (1.4%)
N/A84 (12.7%)

Trials by Status

active_not_recruiting588%
not_yet_recruiting537%
unknown13919%
suspended20%
terminated659%
enrolling_by_invitation30%
recruiting14319%
withdrawn142%
completed25735%

Recent Activity

Clinical Trials (734)

Showing 20 of 734 trialsScroll for more
NCT07146230Phase 2

The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2

Not Yet Recruiting
NCT04789486Phase 1

Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer

Recruiting
NCT07554677Not Applicable

Understanding the Feasibility of a Co-designed Pre-radiotherapy Exercise Programme - A Single-arm Study

Not Yet Recruiting
NCT06729645Not Applicable

External Beam Radiotherapy Combined With Endorectal High-dose-rate Brachytherapy in Elderly and Frail Patients With Rectal Cancer

Not Yet Recruiting
NCT06261047

Radiotherapy Delays Second-line Drug Therapy for Oligo Progressive Primary Liver Cancer

Completed
NCT02421718

Standard Follow-up Program (SFP) for Lung Cancer Patients Treated With Radiotherapy or Chemoradiation

Recruiting
NCT07554482Phase 2

Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma

Not Yet Recruiting
NCT07274774Phase 2

SBRT Plus Systemic Therapy vs Systemic Therapy Alone in BCLC C Hepatocellular Carcinoma

Recruiting
NCT05765812Phase 1

A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

Recruiting
NCT07545967Phase 1

Re-radiotherapy Combined With Chidamide for the Treatment of Recurrent Head and Neck Squamous Cell Carcinoma After Radiotherapy

Recruiting
NCT07554768Phase 2

Neoadjuvant Radio-immunotherapy Versus Immunotherapy Alone for Locally Advanced HNSCC

Not Yet Recruiting
NCT02633514Phase 3

Adjuvant Treatment for Incomplete Resection Thymoma or Thymic Carcinoma

Withdrawn
NCT06402708Phase 3

Postoperative Adjuvant Chemotherapy for Thymic Cancer (FUSCC-Thymic 3)

Recruiting
NCT06532539Phase 2

Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma

Recruiting
NCT06401447Not Applicable

TPF Concurrent Chemo-radiotherapy Plus Immunotherapy for Local Advanced Esophageal Squamous Cell Carcinoma

Active Not Recruiting
NCT02562625Phase 2

Trial of Pembrolizumab and Radiotherapy in Melanoma

Terminated
NCT03755804Phase 2

Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17

Active Not Recruiting
NCT02587455Phase 1

Pembrolizumab and Palliative Radiotherapy in Lung

Completed
NCT07547163

Patient Voice in the Treatment of Low-grade Gliomas: Use of Patient-reported Outcomes, Vorasidenib and Radiotherapy Compared

Recruiting
NCT05009069Phase 2

A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer

Active Not Recruiting

Drug Details

Intervention Type
RADIATION
Total Trials
734